Delivery Order SPE2DB20D9157-SPE2DB25FG62A
- Not listed
- On August 27, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $5,911.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, which has an ultimate completion date of August 28, 2025, was issued without a set-aside designation. The contract is being performed at the contractor's Park Ridge facility and...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc. on September 3, 2025, for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order for delivery to Park Ridge, IL. The contract utilizes a firm fixed-price structure with an ultimate completion date of September 4, 2025, and no set-aside designation...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on September 2, 2025, for the supply of Xtandi 40 mg capsules (120-count) valued at $4,311.35. This firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency responsible for providing logistics support to the Department of Defense. The award carries no set-aside designation, and the contract specifies a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, represents a procurement action under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA. The contract...
- On August 14, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $12,508.77 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (quantity 60). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 15, 2025, and will be performed in Park Ridge, Illinois. This award was issued without a set-aside designation, allowing the woman-owned small business to compete on an unrestricted basis within the...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Xtandi 80 mg tablets. This delivery order is part of a larger single-award indefinite delivery contract (IDC) between the DLA and DMS Pharmaceutical Group, valued up to $499,999,999, that runs through December 31, 2025. The IDC...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, was issued without a set-aside designation. The award represents a single delivery order issued under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $43,113.50 by the Defense Logistics Agency on August 20, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of August 21, 2025, and no set-aside designation was used in the award. Performance will occur at the contractor's facility in Park...
- On August 11, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order covers 120 capsules of Xtandi 40 mg, an oncology treatment medication, under a firm fixed-price contract with an ultimate completion date of August 12, 2025. This award was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete...
- SPE2DB20D9157Indefinite Delivery Contract
- SPE2DB20D9157-SPE2DB25FG62ADelivery Order
On September 8, 2025, the Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, valued at $8,622.72, carries a firm fixed-price structure with an ultimate completion date of September 9, 2025. The delivery order carries no set-aside designation and represents performance at the contractor's Park Ridge, Illinois facility. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. As a major pharmaceutical distributor to Department of Defense healthcare facilities, DMS Pharmaceutical Group maintains a comprehensive portfolio of branded and generic prescription drugs, biologics, and medical consumables. The Xtandi delivery supports the agency's pharmaceutical supply chain requirements for military health facilities, with this particular order addressing oncology medication needs within the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 9/8/25 |